Ovarian cancer and fertility medications: A critical appraisal

Seminars in Reproductive Medicine

Volumn 21, Issue 1, 2003, Pages 65-71

  Kashyap, S ^a   Davis, O K ^a,b  

^a Cornell University ^*  (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Critical appraisal; Fertility drugs; Ovarian cancer

Indexed keywords

ESTROGEN DERIVATIVE; GESTAGEN; GONADOTROPIN DERIVATIVE; ORAL CONTRACEPTIVE AGENT;

CANCER RISK; CARCINOGENESIS; DRUG SAFETY; FERTILIZATION IN VITRO; HORMONAL THERAPY; HUMAN; INFERTILITY; MEDICAL LITERATURE; OVARY CANCER; REVIEW; RISK ASSESSMENT;

ADULT; COHORT STUDIES; FEMALE; FERTILITY AGENTS, FEMALE; HUMANS; INFERTILITY, FEMALE; OVARIAN NEOPLASMS; OVULATION INDUCTION;

EID: 0038277511     PISSN: 15268004     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Levine M, Walter S, Lee H, et al. User's guide to the medical literature IV: how to use an article about harm. JAMA 1994;271:1616-1619
2. Whittemore AS, Harris R, Itnyre J, and the Collaborative Cancer Group. Characteristics relating to ovarian cancer risk - collaborative analysis of 12 US case-control studies II: invasive epithelial cancers in white women. Am J Epidemiol 1992;136:1184-1203
3. Shapiro S. Risk of ovarian cancer after treatment for infertility [letter]. N Engl J Med 1995;332:1301
4. Spritas R, Kaufman SC, Alexander NJ. Fertility drugs and ovarian cancer: red alert or red herring? Fertil Steril 1993;59: 291-293
5. Rosen B, Irvine J, Ritvo P, et al. The feasibility of assessing women's perceptions of the risks and benefits of fertility drug therapy in relation to ovarian cancer risk. Fertil Steril 1997;68:90-94
6. Venn A, Watson L, Bruinsma F, et al. Risk of cancer after use of fertility drugs with in-vitro fertilization. Lancet 1999;354:1586-1590
7. Venn A, Watson L, Lumley J, et al. Breast and ovarian cancer incidence after infertility and in vitro fertilization. Lancet 1995;346:995-1000
8. Stern RC, Dash R, Bentley RC, et al. Malignancy in endometriosis: frequency and comparison of ovarian and extra-ovarian types. Int J Gynecol Path 2001;20:133-139
9. Takahashi K, Kurioka H, Irikoma M, et al. Benign or malignant ovarian neoplasm and ovarian endometriomas. J Am Assoc Gynecol Laparosc 2001;8:278-284
10. Nishida M, Wantanabe K, Sato N, et al. Malignant transformation of ovarian endometriosis. Gynecol Obstet Inv 2000;50:18-25
11. Rossing MA, Daling JR, Weiss NS, et al. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994;331:771-776
12. Ness RB, Cramer DW, Goodman MT, et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 2002;155:217-224
13. Potashnik G, Lerner-Geva L, Genkin L, et al. Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study. Fertil Steril 1999;71:853-859
14. Modan B, Ron E, Lerner-Geva L, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1998;147:1030-1042
15. Fathalla MF. Incessant ovulation: a factor in ovarian neoplasia? [letter]. Lancet 1971;2:163
16. Biskind MS, Biskind GR. Development of tumors in the rat ovary after transplantation into the spleen. Proc Soc Exp Biol Med 1944;55:176
17. Land JA. Ovulation, ovulation induction and ovarian carcinoma. Baillieres Clin Obstet Gynaecol 1993;7:455-472
18. Glud E, Kjaer SK, Troisi R, Brinton LA. Fertility drugs and ovarian cancer. Epidemiol Rev 1998;20:237-257
19. Kuroda H, Konishi I, Mandai M. Ovarian cancer in infertile women, during or after ovulation induction therapy: expression of LH-hCG receptors and sex steroid receptors. Intl J Gynecol Cancer 1997;7:451-457
20. Reis LAG, Kosary CT, Hankey BF, et al. SEER Cancer Statistics Review, 1973-95. Bethesda, MD: National Cancer Institute; 1998
21. DiSaia PJ. Ovarian disorders. In: Scott JR, DiSaia PJ, Hammond CB, Spellacy WN, eds. Danforths Obstetrics and Gynecology. 6th ed. Philadelphia: JB Lippincott; 1990:1067-1120
22. Marrs RP, Hartz SC. Comments on the Possible Association between Ovulation Inducing Agents and Ovarian Cancer. Birmingham, AL: The American Fertility Society; 1993
23. Whittemore AS, Wu ML, Paffenbarger RS, et al. Epithelial ovarian cancer and the ability to conceive. Cancer Res 1989;60:592-560
24. Joly DJ, Lillienfield AM, Diamond EL, et al. An epidemiologic study of the relationship between reproductive experience to cancer of the ovary. Am J Epidemiol 1974;99:190-209
25. Nasca PC, Greenwald P, Chorost S, et al. An epidemiologic case-control study of ovarian cancer and reproductive risk factors. Am J Epidemiol 1984;119:705-713
26. Wu ML, Whittemore AS, Paffenbarger RS, et al. Personal and environmental characteristics related to epithelial ovarian cancer I: reproductive and menstrual events and oral contraceptive use. Am J Epidemiol 1988;128:1216-1227
27. Mosgaard BJ, Lidegaard Ø, Kjaer S, et al. Ovarian stimulation and borderline ovarian tumors: a case-control study. Fertil Steril 1998;70:1049-1055
28. Mosgaard BJ, Lidegaard Ø, Kjaer SK, et al. Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil Steril 1997;67:1005-1012
29. Narod S, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 1998;339: 424-428
30. Ron E, Lunenfeld B, Menczer J, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1987;125:780-790